Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.41 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.41 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134784 | 0.89 | ALDH1A1 (0.50) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL668967 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL668968 | 0.83 | ALDH1A1 (0.44) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL669499 | 0.80 | ACACB (0.35) | HTTNSD2KDM4E | |
| SCHEMBL668399 | 0.77 | CYP2E1 (0.37) | ALDH1A1HTTDYRK1ANSD2KDM4E | |
| SCHEMBL2158381 | 0.77 | KDM4E (0.57) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL668992 | 0.76 | NR1I2 (0.42) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL668991 | 0.76 | NR1I2 (0.42) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL12514492 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MAPTNPC1MAPK1HTT | |
| SCHEMBL102080 | 0.75 | CHEK1 (0.42) | ALDH1A1HTTDYRK1ANSD2EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | ALDH1A1 276/4885MAPT 912/4885NPC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.